OHSU · Knight Cancer Institute
We combine single-cell multiomics and proteomics to understand how genetic and epigenetic heterogeneity shapes hormone response in breast and prostate cancer — toward earlier detection and treatment.
Our mission
The lab is based at Oregon Health and Science University's Knight Cancer Institute, dedicated to detecting and eliminating lethal cancers early.
What we study
We developed RIME to assay endogenous protein complexes — from cancer to embryonic stem cells — and are now building nanoparticle-based approaches to push its sensitivity to a wider range of biological samples.
Using methods like scNMT-seq, we profile tumor cell state at transcriptional and epigenetic resolution — connecting underlying genetic and epigenetic variation to how hormones function in cancer, in cell lines and primary patient samples.
Our technologies
Parallel profiling of the transcriptome, chromatin accessibility, and DNA methylation — in the same single cell.
Read the methodRapid, robust study of protein complexes — in particular chromatin and transcription factor complexes — by mass spectrometry.
Read the methodA topic-modeling machine learning approach that identifies transcriptional cell states in single-cell RNA-seq data.
Read the methodSelected work
Argelaguet*, Clark*, Mohammed* et al. — co-first author
Mohammed et al.
Ors, Chitsazan, Doe, Mulqueen et al. — from the lab
Mohammed et al. — RIME
Meet the scientists behind the work, and see how to join the lab. We recruit at all levels.